Placebo News and Research

RSS

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear.

28 Aug 2018

Low dose Aspirin daily – benefits and risks measured in two studies

Low dose Aspirin has been advocated to reduce the risk of a second heart attack or a stroke or other heart problems in persons who have had one episode. A major new study published in the Lancet, has found that taking Aspirin to prevent the first heart attack fails to work. In fact the risks of taking low dose Aspirin to prevent the first heart attack outweigh the benefits.

27 Aug 2018

Amphetamine regimen does not improve post-stroke motor recovery

A pilot clinical trial exploring the benefit of d-amphetamine combined with physical therapy for stroke patients found no evidence that the regimen improved post-stroke motor recovery.

27 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Aspirin appears to cause major bleeds and have no effect on cancers

Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers.

27 Aug 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late breaking results from the ARRIVE study presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in the Lancet.

27 Aug 2018

Study demonstrates cardiovascular safety of weight loss drug

A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.

27 Aug 2018

Fish oil supplements do not reduce risk of cardiovascular events in patients with diabetes

Fish oil supplements do not prevent heart attacks or strokes in patients with diabetes, according to late breaking results from the ASCEND trial presented today in a Hot Line Session at ESC Congress 2018 and published in the New England Journal of Medicine.

27 Aug 2018

Weight loss pill Lorcaserin found to have low cardiovascular risk

Weight loss pills have been discovered and then withdrawn from the market because of the risks that they pose to the heart. Some of them have raised the risk of heart attacks, suicides, heart valve problems significantly and have been thus banned.

27 Aug 2018

UAB receives NIH grant to continue evaluation of new medication for IPF

The University of Alabama at Birmingham has received a grant from the National Institutes of Health totaling $8.9 million to fund a multiyear program evaluating the role of a new medication in a clinical trial for patients suffering from idiopathic pulmonary fibrosis

24 Aug 2018

Researchers complete testing a new drug to treat rheumatoid arthritis

An international research group led by Charité - Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

23 Aug 2018

New research finds significant link between high Omega-3 Index and depression

New research published in the August edition of the Journal of the American College of Cardiology's Heart Failure issue found significant correlations between blood levels of EPA plus DHA omega-3s in "cognitive" depression among heart failure subjects.

22 Aug 2018

Research uncovers miscarriage cause, identifies potential targets for treatment

Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.

16 Aug 2018

NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

16 Aug 2018

Powerful psychedelic compound can model near-death experiences in the brain

A powerful psychedelic compound found in ayahuasca can model near-death experiences in the brain, a study has found.

15 Aug 2018

Researchers discover new approach to alleviate chronic itch

Two receptors in the spinal cord and the right experimental drug: Researchers at the University of Zurich have discovered a new approach that suppresses itch.

14 Aug 2018

NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease

The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease in individuals who do not have asthma.

14 Aug 2018

FDA approves first oral medication for treatment of adults with Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

10 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

Placebo News and Research

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

Low dose Aspirin daily – benefits and risks measured in two studies

Amphetamine regimen does not improve post-stroke motor recovery

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

Aspirin appears to cause major bleeds and have no effect on cancers

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

Study demonstrates cardiovascular safety of weight loss drug

Fish oil supplements do not reduce risk of cardiovascular events in patients with diabetes

Weight loss pill Lorcaserin found to have low cardiovascular risk

UAB receives NIH grant to continue evaluation of new medication for IPF

Researchers complete testing a new drug to treat rheumatoid arthritis

New research finds significant link between high Omega-3 Index and depression

Research uncovers miscarriage cause, identifies potential targets for treatment

NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine

Powerful psychedelic compound can model near-death experiences in the brain

Researchers discover new approach to alleviate chronic itch

NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease

FDA approves first oral medication for treatment of adults with Fabry disease

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News